Company Overview - Alphatec Holdings specializes in spinal surgery devices, offering a comprehensive portfolio that includes neural monitoring systems, spinal fixation platforms, interbody implants, biologics, and patient positioning solutions [6][7] - The company generates revenue primarily through the sale of proprietary medical devices and related products to hospitals and surgical centers, utilizing a direct sales force and independent distributors in the United States [6] - For the trailing twelve months (TTM), Alphatec reported revenue of $728.02 million and a net income of -$154.96 million, with a share price of $21.01 as of the latest report [4] Recent Transaction - CEO Miles Patrick executed an open-market sale of 100,000 shares for a total consideration of $2.1 million, which reflects a typical transaction size for his historical trading pattern [1][5] - Post-transaction, Patrick's direct holdings decreased by 6.82%, leaving him with 5.14 million shares valued at approximately $108.9 million [2][5] - The shares were sold at around $21.01 each, with the stock closing at $21.20 that day, indicating strong price momentum with a 126.3% increase over the past year [5][10] Operational Performance - Alphatec reported a revenue increase of 30% year over year in its most recent quarter, with surgical revenue climbing 31% to $177 million [10] - Adjusted EBITDA reached $26 million, expanding margins by over 800 basis points, and management raised full-year guidance to approximately $760 million in revenue and about $91 million in adjusted EBITDA [10] Insider Trading Context - The sale was executed under a prearranged Rule 10b5-1 plan, indicating it was a planned liquidity event rather than a directional shift in confidence [11] - Despite the sale, the CEO retains substantial direct and indirect holdings, maintaining alignment with shareholder interests [11]

Core Insights - Ocumetics Technology Corp. is transitioning from a single Chief Medical Officer (CMO) structure to a multi-member Scientific Advisory Committee (SAC) to enhance its medical and clinical leadership as it prepares for pivotal FDA clinical trials anticipated in 2027 [2][4] - The SAC will consist of internationally recognized experts in ophthalmology, medical research, and lens science, aimed at providing diverse oversight critical for successful clinical trials and commercialization [3][4] - The company is focused on advancing its accommodating intraocular lens technology, which is designed to provide clear vision at all distances without the need for corrective lenses [6] Company Developments - The consulting agreement with the current CMO, Dr. Doyle Stulting, will terminate after a ninety-day transition period [1] - The company will announce the members of the SAC in the coming months, indicating a strategic shift in its leadership structure [4] - Dr. Stulting has significantly contributed to Ocumetics' development, and the company expresses gratitude for his service [5] Product and Technology - Ocumetics is currently in the first-in-human early feasibility study phase for its innovative intraocular lens technology [6] - The intraocular lens developed by Ocumetics is designed to fit within the natural lens compartment of the eye, potentially eliminating the need for glasses or contact lenses [6]

Core Viewpoint - The article emphasizes the importance of focusing on stable, long-term investments, particularly in companies known as Dividend Kings, which have consistently increased their dividends for over five decades, indicating strong management and resilient business models [1]. Group 1: Investment Strategy - Income investors are encouraged to be meticulous and prioritize the quality of their investments over high yields [1]. - The article suggests avoiding trends and hype, instead advocating for a focus on companies with a proven track record of dividend growth [1]. Group 2: Stock Selection Process - A stock screener was utilized to identify Dividend Kings that are currently trading at reasonable prices, resulting in a list of eight stocks [2]. - The stocks were arranged based on their forward price-to-earnings (P/E) ratios, with a focus on those that are undervalued compared to sector averages [2][4]. Group 3: Company Profile - Becton Dickinson And Company - Becton Dickinson And Company (BDX) is highlighted as a global leader in medical technology, specializing in medical, laboratory, and diagnostic products [3][5]. - The company has shown innovation and market expansion, particularly with its Phasix™ Mesh hernia prevention program [5]. Group 4: Financial Performance - In its recent quarterly financials, Becton Dickinson reported a sales increase of approximately 8% year-over-year to $5.9 billion, and a net income rise of 23% to $493 million [6]. - The company offers a forward annual dividend of $4.20, resulting in a yield of around 2%, and has a forward P/E ratio of approximately 14, which is below the sector average of 27.10, indicating it is undervalued [6].

Core Insights - Perimeter Medical Imaging AI, Inc. has entered into an agreement with Intermountain Health to deploy its advanced S-Series OCT imaging technology in operating rooms across two hospitals in Utah, enhancing surgical decision-making and patient outcomes [1][3] Company Overview - Perimeter Medical Imaging AI is a commercial-stage medical technology company focused on transforming cancer surgery through ultra-high-resolution, real-time imaging tools [5] - The company's S-Series OCT system provides real-time, cross-sectional visualization of excised tissues at the cellular level and has received FDA clearance [5][6] Partnership Details - The agreement allows any hospital within the Intermountain Health system, which includes 34 hospitals and approximately 400 clinics across multiple states, to acquire Perimeter's imaging technology [2][4] - This collaboration builds on a previous Development Support Agreement aimed at evaluating the potential value of Perimeter's OCT technology and supporting the development of its AI algorithms [3] Technology Impact - The S-Series OCT technology is designed to assist surgeons by providing real-time visualization of tissue margins, which supports more informed surgical decisions [2][3] - The partnership is expected to extend Perimeter's technology into new states, enhancing the capabilities of surgeons and improving patient care [3]

Core Viewpoint - Becton, Dickinson and Company (BDX) is set to announce its fiscal Q1 earnings for 2026, with analysts projecting a decline in profit per share compared to the previous year [1][2]. Financial Performance - Analysts expect BDX to report a profit of $2.82 per share for fiscal Q1 2026, which represents a 17.8% decrease from $3.43 per share in the same quarter last year [2]. - For the full fiscal year 2026, ending in September, BDX is projected to report a profit of $14.85 per share, reflecting a 3.1% increase from $14.40 per share in fiscal 2025 [3]. - The company's EPS is anticipated to grow by 6.3% year-over-year to $15.78 in fiscal 2027 [3]. Stock Performance - BDX shares have declined by 12% over the past 52 weeks, underperforming the S&P 500 Index's return of 17.1% and the State Street Health Care Select Sector SPDR ETF's increase of 13.7% during the same period [4]. - Following the Q4 earnings release on November 6, BDX shares closed up slightly, with total revenue increasing by 8.3% year-over-year to $5.9 billion, meeting consensus estimates [5]. Analyst Ratings - Wall Street analysts maintain a "Moderate Buy" rating for BDX, with four out of twelve analysts recommending "Strong Buy" and eight suggesting "Hold" [6]. - The mean price target for BDX is set at $230, indicating an 11.5% potential upside from current levels [6].

Core Insights - Enovis Corporation will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, at 4:30 p.m. PST [1] - The company focuses on developing clinically differentiated medical technology solutions to enhance patient outcomes and restore motion [2] Company Overview - Enovis is a global innovator in medical technology, dedicated to improving lives through advanced healthcare solutions [2] - The company collaborates with leading health professionals to provide smarter, personalized, and effective care while enhancing operational efficiency for surgeons and clinicians [2] - Enovis solutions positively impact the well-being of millions of patients globally [2] Information Availability - Enovis regularly announces material information through SEC filings, press releases, public conference calls, webcasts, and its Investor Relations website [3] - The company encourages stakeholders to review the information shared on its Investor Relations website for potentially material updates [3]

Core Viewpoint - InMode Ltd. is set to release its financial results for Q4 and the full year of 2025 on February 10, 2026, with preliminary revenue estimates indicating strong performance [1][2][7]. Financial Results - Preliminary revenue for Q4 2025 is expected to be between $103.6 million and $103.8 million, while the full year revenue is projected to be in the range of $370.2 million to $370.4 million [7]. - The non-GAAP gross margin for the full year of 2025 is anticipated to be between 78% and 79% [7]. - Revenue for the full year of 2026 is projected to be between $365 million and $375 million [7]. Conference Call Details - A conference call to discuss the financial results will take place on February 10, 2026, at 8:30 a.m. Eastern Time, featuring key executives including the CEO, CFO, and CTO [3][4]. - Participants are encouraged to pre-register for the call to receive a unique dial-in number for immediate access [4][5]. Company Overview - InMode is recognized as a leading global provider of innovative medical technologies, focusing on devices that utilize novel radio frequency technology for various medical applications [8].

Company Overview - Hologic, Inc. (HOLX) is a global medical technology company with a market cap of $16.7 billion, focused on improving women's health through diagnostic products, medical imaging systems, and surgical solutions [1] Financial Performance - Analysts expect Hologic to report an adjusted EPS of $1.09 for fiscal Q1 2026, reflecting a 5.8% increase from $1.03 in the same quarter last year [2] - For fiscal 2026, the forecasted adjusted EPS is $4.50, representing a 5.6% rise from $4.26 in fiscal 2025, with expectations for a further 10.2% growth to $4.96 in fiscal 2027 [3] Recent Stock Performance - Hologic's stock has increased by 3.1% over the past 52 weeks, which is lower than the S&P 500 Index's gain of 17.1% and the State Street Health Care Select Sector SPDR ETF's return of 14.3% during the same period [4] - Following the Q4 2025 results announced on November 3, Hologic's shares rose slightly after reporting an adjusted EPS of $1.13, an 11.9% year-over-year increase, and revenue of $1.05 billion, which exceeded expectations and grew by 6.2% year-over-year [5] Analyst Sentiment - The consensus rating for Hologic stock is cautious, with a "Hold" rating from 18 analysts, including one "Strong Buy" and 17 "Holds," indicating a less bullish outlook compared to three months ago when eight analysts recommended a "Strong Buy" [6] - The average analyst price target for Hologic is $76.85, suggesting a potential upside of 2.5% from current levels [6]

BOSTON, Jan. 7, 2026 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish third quarter fiscal year 2026 financial results at 6:00 am ET on Thursday, February 5, 2026. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on February 5, 2026. The call can be accessed via teleconference at: Q3 2026 Haemonetics Corporation Earnings Conference Call. Once registration is completed, participants will ...

Core Insights - Sanara MedTech's BIASURGE Advanced Surgical Solution has been awarded an Innovative Technology contract by Vizient, indicating its potential to improve healthcare outcomes and reduce costs in the surgical market [1][3][4] Company Overview - Sanara MedTech Inc. focuses on developing and commercializing transformative technologies aimed at improving clinical outcomes and reducing healthcare expenditures in the surgical market [7][8] - The company offers a range of surgical products, including BIASURGE, CellerateRX Surgical Activated Collagen Powder, and FORTIFY TRG Tissue Repair Graft, among others [8] Product Details - BIASURGE is a no-rinse irrigation solution designed for efficient surgical cleansing, featuring an antimicrobial preservative that provides broad-spectrum effectiveness against pathogenic microorganisms [5][6] - The product is optimized for pH, viscosity, and osmolality to ensure maximum performance while maintaining safety and effectiveness [5] - BIASURGE enhances surgical precision and visibility by maintaining a cleaner operative field, supporting infection-control strategies [6] Contract Significance - The Innovative Technology contract allows Vizient's extensive network of healthcare facilities to access BIASURGE at contracted pricing and pre-negotiated terms, effective January 1, 2026 [3][4] - The contract was awarded based on recommendations from hospital experts, highlighting BIASURGE's unique benefits over existing market products [3][4]